Ovarian cancer trials in Israel

In Israel 21 Also abroad 794

21 trials · From ClinicalTrials.gov, checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
Where
Ashdod, Haifa, Holon, Jerusalem, Nahariya, Petah Tikva, Safed, Tel Aviv, Tel HaShomer
Age
18 years and over
People
420 worldwide
Run by
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
See details and how to joinNCT07546500
Phase 3Taking people
Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian Cancer
Where
Hadera, Haifa, Holon, Jerusalem, Kfar Saba, Nahariya, Tel Aviv
Age
18 years and over
People
950 worldwide
Run by
AstraZeneca
See details and how to joinNCT07851025 · EU 2026-526895-22-00
Phase 3Taking people
A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)
Where
Haifa, Tel Aviv
Age
18 years and over
People
802 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07776691 · EU 2025-524592-22-00
Phase 1/2Taking people
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).
Where
Haifa, Jerusalem, Petah Tikva, Ramat Gan
Age
18 years and over
People
605 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06843447 · EU 2024-514674-47-00
Phase 3Taking people
A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05)
Where
Jerusalem, Tel Aviv
Age
18 years and over
People
646 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07743164 · EU 2025-525130-59-00
Phase 3Taking people
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
Where
Haifa, Jerusalem, Kfar Saba, Petah Tikva, Tel Aviv, Tel HaShomer
Age
18 years and over
People
582 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06819007 · EU 2024-516982-35-00
Phase 1Taking people
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
Where
Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv
Age
18 years and over
People
325 worldwide
Run by
AbbVie
See details and how to joinNCT06084481 · EU 2023-506227-29-00
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Where
Hadera, Haifa, Jerusalem, Kfar Saba, Ramat Gan
Age
18 years and over
People
770 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06824467 · EU 2023-508015-23-00
Phase 1Taking people
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer
Where
Haifa, Jerusalem, Ramat Gan
Age
18 years and over
People
285 worldwide
Run by
AbbVie
See details and how to joinNCT07278336 · EU 2025-522209-40-00
Phase 3Taking people
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
Where
Haifa, Holon, Ramat Gan
Age
18 years and over
People
900 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07318558 · EU 2023-508047-40-00
Phase 1/2Taking people
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
Where
Haifa, Ramat Gan
Age
18 years to 130 years
People
622 worldwide
Run by
AstraZeneca
See details and how to joinNCT05797168 · EU 2022-502576-23-00
Phase 2Taking people
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
Where
Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv
Age
18 years and over
People
377 worldwide
Run by
AbbVie
See details and how to joinNCT07024784
Phase 1/2Taking people
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
Where
Haifa, Jerusalem, Tel HaShomer
Age
18 years and over
People
890 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT03564340 · EU 2024-510783-23-00
Phase 1/2Taking people
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Where
Haifa, Petah Tikva, Ramat Gan, Tel Aviv
Age
18 years and over
People
1,109 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT04895709
Phase 3Taking people
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
Where
Afula, Beersheba, Hadera, Haifa, Holon, Jerusalem, Kfar Saba, Nahariya, Ramat Gan, Sofia, Tel Aviv
Age
18 years and over
People
1,100 worldwide
Run by
AstraZeneca
See details and how to joinNCT07218809 · EU 2025-520466-22-00
Phase 2Taking people
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
Where
Haifa
Age
18 years and over
People
37 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT04641247 · EU 2023-506618-29-00
Phase 1Taking people
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Where
Beer Ya'akov, Haifa, Jerusalem, Kefar Sava, Petah Tikva, Ramat Gan, Tel Aviv
Age
18 years and over
People
694 worldwide
Run by
AbbVie
See details and how to joinNCT05005403
Phase 1/2Taking people
Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors
Where
Jerusalem
Age
18 years and over
People
50
Run by
Hadassah Medical Organization
See details and how to joinNCT00722228
Phase 1/2Taking people
Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers
Where
Jerusalem
Age
18 years to 70 years
People
3
Run by
Hadassah Medical Organization
See details and how to joinNCT05296564
Phase 2Taking people
Inhibiting Beta-adrenergic and COX-2 Signaling During the Perioperative Period to Reduce Ovarian Cancer Progression
Where
Ramat Gan, Tel Aviv
Age
20 years to 85 years
People
60
Run by
Tel-Aviv Sourasky Medical Center
See details and how to joinNCT06839144
Phase 2Taking people
Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer
Where
Ramat Gan
Age
18 years and over
People
24
Run by
Sheba Medical Center
See details and how to joinNCT04519151